https://www.thebodypro.com/category/biktarvy-pro

Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy, B/F/TAF)

The Latest

Black man talking with his doctor in office.
Conference Coverage

B/F/TAF Holds Up as Switch Regimen for Black People Living With HIV, Including Those With Resistance

While the most striking aspect of the study was its demographic focus, the baseline resistance profile of the participants was also key.

By Michael Broder
doctor with trans patient
News

This Week in HIV Research: When Treating Trans Patients, Check Your Priors

Aug. 27, 2020: Traditional CVD risk calculation tools falter for transgender women; switching to B/F/TAF despite NRTI resistance; how tenofovir has altered the HBV landscape; syndemic effects on viral load and blood pressure.

By Barbara Jungwirth and Myles Helfand
illustration of person on cliff with arms raised as sun rises/sets
News

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

By Barbara Jungwirth and Myles Helfand
TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects Img
Conference Coverage

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects

A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.

By Martha Kempner
Are Integrase Inhibitors Linked to Weight Gain? An Evidence Review Img

Are Integrase Inhibitors Linked to Weight Gain? An Evidence Review

Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.

By Polly Clayden for HIV i-Base
Promo Image
News

This Week in HIV Research: Renal Upsides for Tenofovir Alafenamide

E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.

By Barbara Jungwirth and Myles Helfand
Bictegravir Has Finally Arrived: A Top HIV Clinical Development of 2018 Img

Bictegravir Has Finally Arrived: A Top HIV Clinical Development of 2018

I had to double check that it really was earlier this year that bictegravir was U.S. Food and Drug Administration-approved. On Feb. 7, the approval of the fixed-dose formulation of bictegravir with tenofovir alafenamide fumarate and emtricitabine (Bi...

By David Alain Wohl, M.D.
Biktarvy in Women With HIV Img
Women

Biktarvy in Women With HIV

After 48 weeks a study found that Biktarvy was similarly effective and well tolerated as women's other regimens and rates of side effects were relatively low.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange
Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices -- but Really 2 Are Best Img
News

Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices -- but Really 2 Are Best

On March 28, the Department of Health and Human Services Guidelines issued an update to the HIV treatment guidelines, with a focus on the recent approval of bictegravir/TAF/FTC.

By Paul E. Sax, M.D. for NEJM Journal Watch
Bictegravir at CROI 2018: Switching Studies and Drug Resistance Analyses Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Bictegravir at CROI 2018: Switching Studies and Drug Resistance Analyses

Reports about bictegravir, the most recently approved integrase inhibitor, were included in an oral presentation and in several posters at CROI 2018.

By Simon Collins for HIV i-Base